Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Cancer is the leading cause of death among Hispanics/Latinos in the US. Through more public education, community resources and access to care, survival rates are improving.
Breast cancer is the leading cause of cancer death among Hispanic/Latino women. Local community outreach programs have a direct impact on woman being diagnosed and receiving treatment earlier.
Lung cancer is the leading cause of cancer death among Hispanic/Latino men. With strong public messaging, smoking rates are starting to drop in Latino communities.
Taking up the fight to change the Latino cancer landscape are the many dedicated agencies serving their communities throughout the country. Locate the one nearest you HERE.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
Researchers have developed a new method to recreate a robust and functional human immune system in mice using mononuclear cells from the cord blood. This new kind of mice, that count with most of the human immune cell types with lower host-versus-graft disease, are a better experimental platform to study the subtle interactions between the immune system, cancer cells and the tumour microenvironment, in healthy conditions and in disease.
Analyzing the genetics of patients that responded well to checkpoint blockade revealed mutations in the gene Asxl1 in immune T cells. Disrupting the Asxl1 gene in T cells enhanced response to immune checkpoint blockade and improved long-term tumor control in model systems.
Chemists have developed a new chemical reaction that will allow researchers to synthesize selectively the left-handed or right-handed versions of 'mirror molecules' found in nature and assess them for potential use against cancer, infection, depression, inflammation and a host of other conditions.
A new study has punctured a longstanding assumption about the source of the most common type of DNA mutation seen in the genome--one that contributes to many genetic diseases, including cancer.
A new study has found some cancers to be slightly more frequent in people with multiple sclerosis (MS) than in people without MS. Types of cancers found to have a small increased risk include bladder, brain and cervical cancers. The study does not prove that MS increases a person's risk of cancer. It only shows an association.
Researchers have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions. The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in patient samples.